how many people use glp-1 drugs Market Size to Hit USD 132.79 Bn by 2035 5 years ahead: How GLP-1

The global burden has increased substantially over the last twenty years, mirroring the parallel epidemics of obesity and type 2 diabetes mellitus

Additionally, we did not grade comorbid conditions at baseline, which might have caused some selection bias in the cohorts

In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]

Book an appointment with Passion Health Advanced Primary Care for a personalized medical review before starting any weight loss treatment

doi: 10.1038/nm.3009

If meals or workouts ever feel too hard, we adjust the plan so it stays simple and sustainable